
- Teacher: Christian Mosoni
- Teacher: Marco Ruella
This advanced MOOC examines landmark clinical programs that have transformed the field of CAR-T cell therapy. Through twelve representative clinical studies, learners will explore the development, implementation, and long-term evaluation of cellular immunotherapies, with particular emphasis on clinical trial design, toxicity management, biomarkers, patient selection, health equity, and future therapeutic strategies. The course highlights how clinical investigation continuously informs innovation in next-generation cellular therapies.
The course is organized into 12 modules, each consisting of a 10-minute video lecture, downloadable slides, and a formative quiz designed to reinforce the concepts presented.
Module 1 - Bendamustine Lymphodepletion Before Tisagenlecleucel
Module 2 - First-in-Human AT-101 CAR-T Trial
Module 3 - Bendamustine Before Axicabtagene Ciloleucel
Module 4 - Secondary Malignancies After CAR-T Therapy
Module 5 - Vaccine Responsiveness in Lymphoma and Chronic Lymphocytic Leukemia
Module 6 - CAR-T Therapy in Minority Patients
Module 7 - Bendamustine Before Lisocabtagene Maraleucel
Module 8 - Immune-Related Adverse Events After BCMA CAR-T Therapy
Module 9 - Long-Term Safety of Gene-Modified T Cell Therapies
Module 10 - Enhanced CAR-T Therapy After Previous Failure
Module 11 - CAR-T Cell Therapy in Richter Transformation
Module 12 - Predictive Biomarkers of Response to CAR-T Cell Therapy
Each module includes:
-
one video lecture (~10 minutes)
-
downloadable slides
-
a formative quiz (3–5 questions)
Upon successful completion of this MOOC, the learner will be able to:
-
Interpret the design and outcomes of pivotal clinical trials evaluating CAR-T cell therapies.
-
Evaluate different lymphodepletion strategies and their impact on efficacy, toxicity, and patient outcomes.
-
Analyze the biological mechanisms underlying treatment-related toxicities, including cytokine release syndrome, immune-related adverse events, prolonged cytopenias, and secondary malignancies.
-
Assess clinical biomarkers used to predict response, toxicity, and long-term outcomes following CAR-T cell therapy.
-
Critically evaluate evidence supporting patient selection, supportive care strategies, and long-term follow-up after cellular immunotherapy.
-
Compare different clinical approaches for improving efficacy and safety across commercially available and investigational CAR-T products.
-
Integrate clinical evidence, biological mechanisms, and translational discoveries to formulate evidence-based therapeutic strategies.
-
Discuss future directions in clinical cellular immunotherapy, including personalized treatment approaches, biomarker-driven patient management, and next-generation clinical trials.
Quiz assessment
Learners are expected to possess a solid background in:
-
immunology
-
molecular biology
-
oncology
-
hematology
Completion of the previous MOOCs in the series is strongly recommended:
-
Foundations of Adoptive T-Cell Immunotherapy
-
Translational Innovations in CAR-T Cell Therapy
Marco Ruella
marco.ruella@unito.it
For technical issues:
edvancedeh@unito.it